Breast milk soluble vascular endothelial growth factor receptor-1 and implications for health

2013 ◽  
pp. 437-446
Author(s):  
T. Ozgurtas
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Breast Milk ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

Soluble Vascular Endothelial Growth Factor Receptor 1 in Human Breast Milk

2011 ◽  
Vol 76 (1) ◽  
pp. 17-21 ◽  
Author(s):  
Taner Ozgurtas ◽  
Ibrahim Aydin ◽  
Ozden Turan ◽  
Esin Koc ◽  
Ibrahim M. Hirfanoglu ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Breast Milk ◽  
Growth Factor Receptor ◽  
Human Breast Milk ◽  
Vascular Endothelial ◽  
Human Breast ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document